Poorgradstudent,
I am pleased at the Carfilzomib data and the market response to ONXX today. I think it significantly raises the prospects for a buyout of ONXX. One interesting tidbit mentioned on the ONXX board, and I checked it out myself to verify it, is some news about the ONXX-Bayer partnership agreement. ONXX stated that the deal resets after 5 years, which is deal this Dec 20th. After that, even if ONXX gets bought, the revenue sharing will be similar to what it is now.
Market Data 
Markets 
AI
